GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Khiron Life Sciences Corp (OTCPK:KHRWF) » Definitions » Quick Ratio

Khiron Life Sciences (Khiron Life Sciences) Quick Ratio : 0.89 (As of Sep. 2022)


View and export this data going back to 2021. Start your Free Trial

What is Khiron Life Sciences Quick Ratio?

The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. It is calculated as a company's Total Current Assets excludes Total Inventories divides by its Total Current Liabilities. Khiron Life Sciences's quick ratio for the quarter that ended in Sep. 2022 was 0.89.

Khiron Life Sciences has a quick ratio of 0.89. It indicates that the company cannot currently fully pay back its current liabilities.

The historical rank and industry rank for Khiron Life Sciences's Quick Ratio or its related term are showing as below:

KHRWF' s Quick Ratio Range Over the Past 10 Years
Min: 0.05   Med: 3.19   Max: 11.92
Current: 0.89

During the past 10 years, Khiron Life Sciences's highest Quick Ratio was 11.92. The lowest was 0.05. And the median was 3.19.

KHRWF's Quick Ratio is not ranked
in the Drug Manufacturers industry.
Industry Median: 1.32 vs KHRWF: 0.89

Khiron Life Sciences Quick Ratio Historical Data

The historical data trend for Khiron Life Sciences's Quick Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Khiron Life Sciences Quick Ratio Chart

Khiron Life Sciences Annual Data
Trend May12 May13 May14 May15 May16 May17 Dec18 Dec19 Dec20 Dec21
Quick Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.08 3.59 5.19 3.82 1.86

Khiron Life Sciences Quarterly Data
Nov17 Feb18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22
Quick Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.42 1.86 1.10 1.44 0.89

Competitive Comparison of Khiron Life Sciences's Quick Ratio

For the Drug Manufacturers - Specialty & Generic subindustry, Khiron Life Sciences's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Khiron Life Sciences's Quick Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Khiron Life Sciences's Quick Ratio distribution charts can be found below:

* The bar in red indicates where Khiron Life Sciences's Quick Ratio falls into.



Khiron Life Sciences Quick Ratio Calculation

The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.

Khiron Life Sciences's Quick Ratio for the fiscal year that ended in Dec. 2021 is calculated as

Quick Ratio (A: Dec. 2021 )=(Total Current Assets-Total Inventories)/Total Current Liabilities
=(18.573-7.386)/6.029
=1.86

Khiron Life Sciences's Quick Ratio for the quarter that ended in Sep. 2022 is calculated as

Quick Ratio (Q: Sep. 2022 )=(Total Current Assets-Total Inventories)/Total Current Liabilities
=(13.739-7.357)/7.205
=0.89

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Khiron Life Sciences  (OTCPK:KHRWF) Quick Ratio Explanation

The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.

In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.

The higher the quick ratio, the better the company's liquidity position.


Khiron Life Sciences Quick Ratio Related Terms

Thank you for viewing the detailed overview of Khiron Life Sciences's Quick Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Khiron Life Sciences (Khiron Life Sciences) Business Description

Traded in Other Exchanges
N/A
Address
2300 - 500 Burrard Street, Vancouver, BC, CAN, V6C 2B5
Khiron Life Sciences Corp is a vertically integrated medical company with core operations in Latin America and Europe, The company's platform leverages medical health clinics and proprietary telemedicine platforms, Khiron combines a patient-oriented approach, physician education programs, scientific, product innovation, and cannabis operations expertise to drive prescriptions and brand loyalty with patients worldwide. The company has a presence in Mexico, Peru, Germany, the United Kingdom, and Brazil.